

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemolytic anemia autoimmune | D000744 | EFO_1001264 | D59.10 | 1 | 3 | — | — | — | 3 |
| Anemia | D000740 | EFO_0004272 | D64.9 | 1 | 2 | — | — | — | 2 |
| Hemolysis | D006461 | — | — | 1 | 2 | — | — | — | 2 |
| Hemolytic anemia | D000743 | — | D55-D59 | 1 | 2 | — | — | — | 2 |
| Pemphigus | D010392 | EFO_1000749 | L10 | 1 | 1 | — | — | — | 1 |
| Myasthenia gravis | D009157 | EFO_0004991 | G70.0 | — | 1 | — | — | — | 1 |
| Muscle weakness | D018908 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | 1 | — | — | — | — | 1 |
| Drug common name | ORILANOLIMAB |
| INN | orilanolimab |
| Description | Orilanolimab is an antibody pharmaceutical. It is currently being investigated in clinical studies. |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | — |
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4298117 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 1LTT6HMX9N (ChemIDplus, GSRS) |
